R&D News | pharmaphorum

News

Beckley Psytech's chief scientific and medical officer Dr Rob Conley

Beckley's psychedelic med inches forward in depression

UK psychedelic medicines developer Beckley Psytech has said its candidate for treatment-resistant depression has enhanced the effect of standard antidepressants in a phase 2 trial.

News

UK trumpets £1bn investment plan from BioNTech

BioNTech has said it will commit up to £1bn in investment in the UK over the next decade, in what has been described as a "template" for the sector.

News

O'Shaughnessy says UK clinical trials sector is on the mend

After losing ground in commercial clinical trials in recent years, the UK has now turned a corner and is once again taking a "global lead."

News

Imec showcases ingestible sensor for gut studies

Imec will demonstrate an ingestible sensor device today that can monitor gut health and could be a valuable tool for research and clinical trials.

News

UK's long-term R&D investment policy welcomed

The decision by the UK to set new 10-year budgets for public R&D funding has received a positive response from academia and the pharma industry.

News

Pfizer snaps up PD-1/VEGF drug from China's 3SBio

Pfizer has joined the ranks of those developing cancer drugs that target PD-1 and VEGF, penning a $6bn licensing deal with China's 3SBio.

Beckley's psychedelic med inches forward in depression

UK trumpets £1bn investment plan from BioNTech

O'Shaughnessy says UK clinical trials sector is on the mend

Imec showcases ingestible sensor for gut studies

UK's long-term R&D investment policy welcomed

Pfizer snaps up PD-1/VEGF drug from China's 3SBio

Making direct-to-patient work, with Matt Wadyka

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks